 |
|
|
| | | | | | Dear colleagues,
| | | | | | | | At the 2019 ASH1 Annual Meeting in Orlando, a large number of interesting topics will be presented.
| | | | | |
|
| | | | | | Hot Topics in Hodgkin Lymphoma | | | | | | | | A multitude of abstracts addressing all aspects of Hodgkin Lymphoma will be presented at this year´s ASH meeting. Results from studies implementing checkpoint inhibitors into first-line treatment of HL will be shown. Those include the GHSG NIVAHL study investigating the combination of nivolumab and AVD chemotherapy in newly diagnosed intermediate-stage classical HL (read on the ASH website). A similar US study applied three doses of pembrolizumab before AVD chemotherapy for 4 to 6 cycles (read on the ASH website). A chemotherapy-free regimen consisting of nivolumab and brentuximab vedotin was used in a study that included older patients with newly diagnosed classical HL (read on the ASH website).
| | | | | | | | In the relapsed setting, follow-up data from a phase I/II study using the combination of nivolumab and brentuximab vedotin as salvage prior to high-dose chemotherapy will be presented (read on the ASH website). In addition, studies evaluating nivolumab (read on the ASH website) or brentuximab vedotin in combination with ICE as salvage will be shown (read on the ASH website).
| | | | | | | | Other abstracts include preliminary results from studies evaluating novel drugs in patients with multiple relapses.
| | | | | | | | The Scientific Committee of the International Symposium on Hodgkin Lymphoma (ISHL) will meet in Orlando to discuss the scientific program of our congress. ISHL12 will take place in Cologne, Germany, between October 24 to 26, 2020.
| | | | | |
|
|
|
|
| | | | | | | | | 1 Please note that ISHL12 is not affiliated with the American Society of Hematology.
| | | | | | | | | | Please add to your address book to prevent spam filters from blocking these E-Mails.
| | | | | | | | | | For more information please click here.
| | | | | | | | |
|
